Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

X
Drug Profile

Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

Alternative Names: NH-001

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroHealing Pharmaceuticals
  • Developer Cato Research; NeuroHealing Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coma
  • New Molecular Entity No
  • Available For Licensing Yes - Coma

Highest Development Phases

  • Suspended Coma

Most Recent Events

  • 26 Apr 2013 NeuroHealing Pharmaceuticals suspends enrolment in its Phase-II trial for Coma in USA (NCT00761228)
  • 23 May 2011 NeuroHealing Pharmaceuticals receives Orphan Drug status for apomorphine for Coma in European Union
  • 16 May 2011 NeuroHealing Pharmaceuticals and Cato BioVentures (Cato Research) agree to co-develop apomorphine for Coma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top